The genomic landscape of response to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies cetuximab and panitumumab, which prevent epidermal growth factor receptor (EGFR) activation. Recent studies have identified alterations in KRAS and other genes as likely mechanisms of primary and secondary resistance to anti-EGFR antibody therapy. Despite these efforts, additional mechanisms of resistance to EGFR blockade are thought to be present in colorectal cancer and little is known about determinants of sensitivity to this therapy. To examine the effect of somatic genetic changes in colorectal cancer on response to anti-EGFR antibody therapy, here we perform complete exome sequence and copy number analyses of 129 patient-derived tumour grafts and targeted genomic analyses of 55 patient tumours, all of which were KRAS wild-type. We analysed the response of tumours to anti-EGFR antibody blockade in tumour graft models and in clinical settings and functionally linked therapeutic responses to mutational data. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Novel alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade. Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were identified in tumours with increased sensitivity to anti-EGFR therapy. Therapeutic resistance to EGFR blockade could be overcome in tumour graft models through combinatorial therapies targeting actionable genes. These analyses provide a systematic approach to evaluating response to targeted therapies in human cancer, highlight new mechanisms of responsiveness to anti-EGFR therapies, and delineate new avenues for intervention in managing colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in late-line therapy, only 12–17% of patients have durable responses to anti-EGFR monotherapy [4]”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Gene mutations downstream of the EGFR signalling pathway, including RAS/RAF/MEK and PI3K/AKT/mTOR, significantly contribute to drug resistance [9–11].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is supported by our observation, consolidated after monitoring hundreds of mCRC PDXs exposed to cetuximab (10, 25, 27, 29, 30), that complete responses are exceptional events.”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“A growing number of studies suggest that mutations in the extracellular domain (ECD) of the EGFR, such as S492R, G465E, R451C and K467T, prevent binding cetuximab and make CRC resistant to anti-EGFR mAbs [141,142,143,144].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288 · cited 1×
“Sequence reads were aligned against the human reference genome (version hg18) using ELAND with additional realignment of select regions using the Needleman-Wunsch method 35 .”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“A mutation in the tumour was identified as a candidate somatic mutation only when (1) distinct paired reads contained the mutation in the tumour, (2) the number of distinct paired reads containing a particular mutation in the tumour was at least 2% of the total distinct read pairs for targeted analyses and 10% of read…”
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Self-citationPDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 6×
“Common CRC driver genes were identified at expected frequencies in the tumours analysed (Supplementary Tables 3–5).”
InfluentialSelf-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F., Rule, S. A., Teixeira, A., Walewski, J. A., Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045 · Cited by 1,631
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Cited by
Items 201–300 of 478
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 26
“or activating mutation, has been described as a singular mechanism of primary and acquired resistance to anti-EGFR therapy in KRAS wildtype CRC (Barry, Cheang, Chang, & Kennecke, 2016; Bertotti et al., 2015; Kavuri et al., 2015; Martin et al., 2013).”
BackgroundInfluentialIRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma
Zhu, S., Ward, B. M., Yu, J., Matthew-Onabanjo, A. N., Janusis, J., Hsieh, C.-C., Tomaszewicz, K., Hutchinson, L., Zhu, L. J., Kandil, D. H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97398 · Cited by 26
“In more recent genome sequencing studies, IRS2 somatic mutations were identified in CRC as well, although the consequences of these alterations on tumor cell function were not directly investigated (26).”
BackgroundPatient-Derived Xenograft Models in Cervical Cancer: A Systematic Review
Tanaka, T., Nishie, R., Ueda, S., Miyamoto, S., Hashida, S., Konishi, H., Terada, S., Kogata, Y., Sasaki, H., Tsunetoh, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179369 · Cited by 28
The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance
Chen, Z., Wang, G., Guo, M., Zhu, N., Chen, X., Yan, Y., Li, N., & Yu, W. (2024) · Cancer Control · doi:10.1177/10732748241274196 · Cited by 25
“41,42”
Precision oncology: lessons learned and challenges for the future
Yang, H., Shah, R. H., Tegay, D. H., & Onel, K. (2019) · Cancer Management and Research · doi:10.2147/cmar.s201326 · Cited by 28
“NSCLC were accurately modeled before crystal structures were available).(100) Notably, these five approaches are not”
MethodGao, L., Xu, J., He, G., Huang, J., Xu, W., Qin, J., Zheng, P., Ji, M., Chang, W., Ren, L., et al. (2019) · PubMed · Cited by 25
Systems Biology and Experimental Model Systems of Cancer
Yalçın, G. D., Danisik, N., Baygin, R. C., & Acar, A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040180 · Cited by 27
“Importantly, one of these studies played a critical role in assessing the genomic landscape of anti-EGFR antibody blockage in PDXs and functional consequences linked to clinical data in cancer patients [87].”
BackgroundA Nanobody‐Conjugated DNA Nanoplatform for Targeted Platinum‐Drug Delivery
Wu, T., Liu, J., Liu, M., Liu, S., Zhao, S., Tian, R., Wei, D., Liu, Y., Zhao, Y., Xiao, H., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201909345 · Cited by 24
Genetic alterations shaping tumor response to anti-EGFR therapies
Vaquero, J., Pavy, A., Gonzalez‐Sanchez, E., Meredith, M., Arbelaiz, A., & Fouassier, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100863 · Cited by 26
Picco, G., Petti, C., Sassi, F. P., Grillone, K., Migliardi, G., Rossi, T., Isella, C., Nicolantonio, F. D., Sarotto, I., Sapino, A., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw209 · Cited by 27
Self-citationBianchi, A. S., Siena, S., Tonini, G., Bardelli, A., & Santini, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.006 · Cited by 25
Self-citationFeedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
Bosch-Vilaró, A., Jacobs, B., Pomella, V., Asbagh, L. A., Kirkland, R. E., Michel, J., Singh, S., Liu, X., Kim, P., Weitsman, G. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13834 · Cited by 26
“com/oncotarget amplifications have been identified as plausible innate resistance mechanisms to EGFR targeted therapy in colorectal cancer [15], as well as ALK, FGFR2, NTRK1/2 and RET kinase addition [16].”
BackgroundChallenges in Stratifying the Molecular Variability of Patient-Derived Colon Tumor Xenografts
Cybulska, M., Olesiński, T., Goryca, K., Paczkowska, K., Statkiewicz, M., Kopczyński, M., Grochowska, A., Unrug-Bielawska, K., Tyl-Bielicka, A., Gajewska, M. E., et al. (2018) · BioMed Research International · doi:10.1155/2018/2954208 · Cited by 26
Delord, J., Argilés, G., Fayette, J., Wirth, L. J., Kasper, S., Siena, S., Mesía, R., Berardi, R., Cervantes, A. M. R., Dekervel, J., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00928-z · Cited by 25
Self-citationLiu, K., Hu, H., Jiang, H., Liu, C., Zhang, H., Gong, S., Wei, D., & Yu, Z. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23245 · Cited by 27
Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 26
Self-citationGeng, Y., Xia, W., Zheng, X., Chen, L., Zhou, Y., Feng, J., Yuan, Y., Zhang, M., Lu, J., Wei, S., et al. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01986-x · Cited by 25
Brijwani, N., Jain, M., Dhandapani, M., Zahed, F., Mukhopadhyay, P., Biswas, M., Khatri, D., Radhakrishna, V. D., Majumder, B., Radhakrishnan, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01566-x · Cited by 24
Huang, K.-B., Liu, R., Peng, Q.-H., Li, Z.-S., Jiang, L.-J., Guo, S., Zhou, Q.-H., Liu, T.-Y., Deng, C.-Z., Yao, K., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.016 · Cited by 23
Choi, I. S., Kato, S., Fanta, P. T., Leichman, L., Okamura, R., Raymond, V. M., Lanman, R. B., Lippman, S. M., & Kurzrock, R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0965 · Cited by 23
“amplification of KRAS, ERBB2, and MET - consistent with the implication of many of these genes in both primary as well as acquired resistance to anti-EGFR therapy (29, 34-36, 42, 43, 45-49) (see illustrative case, Figure 2).”
BackgroundRenzi, G. D., Gaballo, G., Gazzaniga, P., & Nicolazzo, C. (2020) · Oncology · doi:10.1159/000510944 · Cited by 27
Biomarker-driven and molecular targeted therapies for colorectal cancers
Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.003 · Cited by 27
“Several genes involved in primary resistance to anti-EGFRs have been identified in RAS wild-type mCRC, based on preclinical data and retrospective evaluations, including MET amplification, HER2 amplification, phosphatidylinositide-3kinase ( PIK3CA ) mutations (exon 9 and 20 hotspot mutations), FGFR1 and PDGFRA mutatio…”
MethodPost, J. B., Hami, N., Mertens, A. E. E., Elfrink, S., Bos, J. L., & Snippert, H. J. G. (2019) · Oncotarget · doi:10.18632/oncotarget.26677 · Cited by 23
Li, Q., Dai, W., Liu, J., Li, Y., & Li, Y. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1785-7 · Cited by 24
Self-citationPreclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
Dang, Q., Zuo, L., Hu, X., Zhou, Z., Chen, S., Liu, S., Ba, Y., Zuo, A., Xu, H., Weng, S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70041 · Cited by 32
Cremolini, C., Montagut, C. O., Ronga, P., Venturini, F., Yamaguchi, K., Stintzing, S., & Sobrero, A. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.946850 · Cited by 25
“9 Acneiform rash (17), hypomagnesemia (13) and dry skin (13)”
BackgroundColorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment
Liu, Q.-L., Zhou, H., Zhou, Z., & Chen, H. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10107-0 · Cited by 26
Clinical target sequencing for precision medicine of breast cancer
Tsuchida, J., Rothman, J. D., McDonald, K.-A., Nagahashi, M., Takabe, K., & Wakai, T. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1373-5 · Cited by 24
Graves‐Deal, R., Bogatcheva, G. T., Rehman, S., Lu, Y., Higginbotham, J. N., & Singh, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26663 · Cited by 26
Li, Y., Wang, B., Ma, F., Jiang, D., Wang, Y., Li, K., Tan, S., Feng, J., Wang, Y., Qin, Z., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101311 · Cited by 31
Zhu, Z., Shen, J., Ho, P. C., Hu, Y., Ma, Z., & Wang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1563198 · Cited by 34
Fu, S., Liu, X., Luo, M., Xie, K., Nice, E. C., Zhang, H., & Huang, C. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1299006 · Cited by 27
“In conclusion, proteogenomics strategies have identified a number of novel candidate cancer biomarkers related with response to chemotherapy in CRC.”
BackgroundMethodInfluentialRobertis, M. D., Greco, M. R., Cardone, R. A., Mazza, T., Marzano, F., Mehterov, N. H., Kazakova, M., Belev, N., Tullo, A., Pesole, G., et al. (2022) · Cells · doi:10.3390/cells11223568 · Cited by 24
Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
Yoshikawa, A., & Nakamura, Y. (2022) · Cancers · doi:10.3390/cancers15010183 · Cited by 22
Chen, G., Yang, Z., Eshleman, J. R., Netto, G. J., & Lin, M. (2016) · BioMed Research International · doi:10.1155/2016/9850690 · Cited by 24
“(i) Primary resistance to anti-EGFR mAb KRAS and NRAS [7, 8, 12, 14–19]; BRAF [7, 20–22]; PIK3CA [7]; other potential markers (ERBB2, EGFR, FGFR1, PDGFRA, andMAP2K1) [102]”
BackgroundCopy number profiles of paired primary and metastatic colorectal cancers
Kawamata, F., Patch, A., Nones, K., Bond, C., McKeone, D., Pearson, S., Homma, S., Liu, C., Fennell, L., Dumenil, T. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23277 · Cited by 26
“For example, DNA copy number amplifications in KRAS, ERBB2, MET and FGFR1 have been found to be predictors of poor prognosis and resistance to anti-EGFR therapy for CRC patients [13, 14].”
BackgroundRepurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
Yang, M., Schell, M. J., Loboda, A. P., Nebozhyn, M., Li, J., Teer, J. K., Pledger, W. J., & Yeatman, T. J. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1383 · Cited by 23
“and colleagues n1⁄4 98PDXmodels (24)], which also hadAPC and TP53 mutation data (see Supplementary Tables S7 and S8).”
BackgroundMazzeschi, M., Sgarzi, M., Romaniello, D., Gelfo, V., Cavallo, C., Ambrosi, F., Morselli, A., Miano, C., Laprovitera, N., Girone, C., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02309-1 · Cited by 24
“Anaplastic lymphoma kinase (ALK) is a large, glycosylated receptor tyrosine kinase (RTK) that belongs to the superfamily of the insulin receptors, showing a great similarity to leukocyte receptor tyrosine kinase (LTK, 79% identity) [8, 9].”
BackgroundBattaglin, F., Ou, F., Qu, X., Höchster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Ashouri, K., Zemla, T., Blanke, C. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01507 · Cited by 25
Leto, S. M., Grassi, E., Avolio, M., Vurchio, V., Cottino, F., Ferri, M., Zanella, E. R., Borgato, S., Corti, G., di Blasio, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51909-2 · Cited by 24
“As shown previously 14,16 , ERBB2 -ampli fi ed PDXs failed to respond to cetuximab (Fig.”
InfluentialSelf-citationShimada, Y., Muneoka, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Hirose, Y., Ando, T., Nakano, M., Sakata, J., Kameyama, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39328-6 · Cited by 19
Haist, C., Poschinski, Z., Bister, A., Hoffmann, M. J., Grunewald, C. M., Hamacher, A., Kassack, M. U., Wiek, C., Scheckenbach, K., & Hanenberg, H. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.105867 · Cited by 21
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancer
Costigan, D. C., & Dong, F. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22813 · Cited by 24
“In one study, complete exome sequencing and targeted genomic analyses of KRAS wild-type patient tumors identified novel mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to therapy.(71) Additional studies examined circulating tumor DNA in blood of colorectal cancer patie…”
BackgroundIce, R. J., Chen, M. M., Sidorov, M., Ho, T. L., Woo, R. W. L., Rodriguez-Brotons, A., Luu, T., Jian, D., Kim, K. B., Leong, S. P. L., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0696-y · Cited by 22
Gmeiner, W. H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242224 · Cited by 18
“with acquired resistance to anti-EGFR therapy.(44)”
Lièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Selves, J., Lecomte, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.353 · Cited by 18
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 20
Zhang, M., Wang, H., Li, H., Zhou, Y., Peng, R., Liu, J., & Zhao, Q. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.5574 · Cited by 25
“Clinically, wild-type KRAS patients with advanced CRC are selected to treat with monoclonal EGFR antibodies, such as panitumumab and cetuximab, while the majority of KRAS mutant patients are resistant (Bertotti et al. , 2015; Patil et al. , 2017; Zhai et al., 2017).”
Assessing therapy response in patient-derived xenografts
Ortmann, J., Rampášek, L., Tai, E., Mer, A. S., Shi, R., Stewart, E., Mascaux, C., Fares, A. F., Pham, N., Beri, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf4969 · Cited by 19
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 25
Muñoz-Galván, S., Rivero, M., Peinado-Serrano, J., Martínez‐Pérez, J., Fernández-Fernández, M., Ortiz, M. J., García-Heredia, J. M., & Carnero, A. (2020) · Cells · doi:10.3390/cells9051071 · Cited by 17
“secondary resistance to therapy using anti-EGFR antibody in CRC [51].”
BackgroundDrug Discovery Oncology in a Mouse: concepts, Models and Limitations
Long, J. E., Jankovic, M., & Maddalo, D. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0019 · Cited by 20
Perron, U., Grassi, E., Chatzipli, A., Viviani, M., Karakoç, E., Trastulla, L., Brochier, L. M., Isella, C., Zanella, E. R., Klett, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53163-y · Cited by 17
“Previous comprehensive genetic characterisations of CRC models have shown that the frequency of common genetic mutations observed in PDXs is similar to that observed in primary tumours 2,3,20,21,32,33 .”
InfluentialSelf-citationSubclonal response heterogeneity to define cancer organoid therapeutic sensitivity
Kratz, J. D., Rehman, S., Johnson, K. A., Gillette, A. A., Sunil, A., Favreau, P. F., Pasch, C. A., Miller, D. D., Zarling, L. C., Yeung, A. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96204-2 · Cited by 21
Russo, R., Matrone, N., Belli, V., Ciardiello, D., Valletta, M., Esposito, S., Pedone, P. V., Ciardiello, F., Troiani, T., & Chambery, A. (2019) · Cancers · doi:10.3390/cancers11101430 · Cited by 18
“Nevertheless, a significant number of patients with no detectable mutations in KRAS failed to respond to cetuximab treatments whereas patients harboring KRAS mutations are sensitive to cetuximab-based therapies, suggesting the occurrence of additional mechanisms at the basis of cetuximab responsiveness [40].”
BackgroundInfluentialPalmer, A. C., Plana, D., Gao, H., Korn, J. M., Yang, G., Green, J., Zhang, X., Velazquez, R., McLaughlin, M. E., Ruddy, D. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3850 · Cited by 17
“Informative PDX-based preclinical studies of patient-to-patient variability in drug response have been reported for lung, breast, colon, melanoma, and pancreatic cancers, including a previously described encyclopedia of >1,000 PDXs (10, 16, 17).”
BackgroundJemii, N. B., Tounsi, H., Yaïche, H., Mezghanni, N., Jaballah-Gabteni, A., Fehri, E., Fayala, C. B., Abdelhak, S., & Boubaker, S. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02614-3 · Cited by 17
Owen, D. R., Wong, H., Bonakdar, M., Jones, M. R., Hughes, C. S., Morin, G. B., Jones, S. J. M., Renouf, D. J., Lim, H. J., Laskin, J. J., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a002535 · Cited by 17
“Several other molecular alterations have been associated with resistance to EGFR-directed therapy in CRC (Bertotti et al. 2015), although none were detected in Case 1.”
BackgroundSelf-citationMauri, G., Durinikova, E., Amatu, A., Tosi, F., Cassingena, A., Rizzetto, F., Buzo, K., Arcella, P., Aquilano, M. C., Bonoldi, E., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00143 · Cited by 23
Self-citationChakrabandhu, K., & Hueber, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00429 · Cited by 17
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
Kasper, S., Reis, H., Ziegler, S., Nothdurft, S., Mueller, A. M., Goetz, M., Wiesweg, M., Phasue, J., Ting, S. C., Wieczorek, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17438 · Cited by 18
“Additional aberrations associated with resistance to anti-EGFR antibody therapy in mCRC comprise amongst others amplification, mutations or overexpression of the human epidermal growth factor receptor 2 (HER2) and HER3, the hepatocyte growth factor receptor (c-MET), the platelet-derived growth factor receptor A (PDGFR…”
BackgroundArai, H., Elliott, A., Millstein, J., Xiu, J., Ou, F., Innocenti, F., Wang, J., Battaglin, F., Jayachandran, P., Kawanishi, N. K., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02074-z · Cited by 16
“In the MSS/pMMR subgroup, similar trends were observed regarding the frequency of RAS-MT (41.7% vs. 53.7%, p= 0.002) and PTEN-mutant (15.6% vs. 3.1%, p < 0.001; Fig.”
BackgroundInfluentialWang, C., Sandhu, J. S., & Fakih, M. (2022) · The Oncologist · doi:10.1093/oncolo/oyab028 · Cited by 17
“36 Additionally, studies have shown that SMAD4 mutation may lead to resistance to anti-EGFR therapy.”
Khalafizadeh, A., Hashemizadegan, S. D., Shokri, F., Bakhshinejad, B., Jabbari, K., Motavaf, M., & Babashah, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18197 · Cited by 17
Novel insights into transcriptional dysregulation in colorectal cancer
Feodorova, Y. N., Tashkova, D., Koev, I. G., Todorov, A. T., Kostov, G., Simitchiev, K., Belovejdov, V., Dimov, R., & Sarafian, V. S. (2018) · Neoplasma · doi:10.4149/neo_2018_170707n467 · Cited by 15
Mouse models in the era of large human tumour sequencing studies
de Ruiter, J. R., Wessels, L. F. A., & Jonkers, J. (2018) · Open Biology · doi:10.1098/rsob.180080 · Cited by 18
Uhlyarik, A., Piurkó, V., Pápai, Z., Rásó, E., Lahm, E., Kiss, É., Sikter, M., Vachaja, J., Kenessey, I., & Tímár, J. (2020) · Cancers · doi:10.3390/cancers12030614 · Cited by 16
“On the other hand, mutations of the extracellular domain of EGFR (at codon 492 or 465) were found to be associated with cetuximab resistance [12,13].”
Long noncoding RNAs in intestinal homeostasis, regeneration, and cancer
Yadav, V., Kumar, A., Tripathi, P. P., & Gupta, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30393 · Cited by 15
“In addition, the acquisition of de novo resistance to anti‐EGFR treatment cetuximab has been attributed to several acquired mutations, especially KRAS activating mutations (Bertotti et al., 2015; Misale et al., 2014).”
BackgroundDoyle, H. A., Koski, R. A., Bonafé, N., Bruck, R. A., Tagliatela, S., Gee, R. J., & Mamula, M. J. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2218-9 · Cited by 16
Park, J. S., Yoon, G., Kim, H. J., Park, S. Y., Choi, G., Kang, M. K., Kim, J. G., Jang, J.-S., & Seo, A. N. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2409-y · Cited by 16
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00926-7 · Cited by 17
“In addition, overexpression of downstream tyrosine kinase receptors including FGFR1, FGFR2, KIT, and PDGFRA was identified as a genetic primary resistance mechanism [13, 86].”
BackgroundRedefining Colorectal Cancer by Tumor Biology
Salem, M. E., Puccini, A., & Tie, J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279867 · Cited by 14
Top advances of the year: Precision oncology
Desai, A. P., Reddy, N. K., & Subbiah, V. (2023) · Cancer · doi:10.1002/cncr.34743 · Cited by 17
“Also, 5% of metastatic colon cancers (mCRC) are driven by HER2 amplification or mutation.(33) HER2‐amplified CRC typically clusters in sigmoid colon.”
BackgroundZheng, P., Liang, C., Ren, L., Zhu, D., Feng, Q., Chang, W., He, G., Ye, L., Chen, J., Lin, Q., et al. (2018) · Journal of Oncology · doi:10.1155/2018/5072987 · Cited by 15
Kim, S., Kim, J., Suh, K. J., Chang, W., Kim, J. W., Oh, H., Cho, J. Y., Kim, J. H., Cho, S., Kim, J. H., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03233-7 · Cited by 14
Genomic landscape of gallbladder cancer: insights from whole exome sequencing
Awasthi, S., Kumar, R., Pradhan, D., Rawal, N., Goel, H., Sahu, P., Sisodiya, S., Rana, R., Kumar, S., Dash, N. R., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002031 · Cited by 15
“…include p. G284R, p.E298G reported in cholangiocarcinoma, breast, and colon cancer [71] , p.V104L found in bladder and colon cancer [72] , p.P262H, documented in colon and ovarian cancer [73] and p. V104M mutations, identi fi ed in cholangiocarcinoma, breast cancer, and endometrial cancer [74] .”
Recent advances in the development of transplanted colorectal cancer mouse models
Yang, Y.-S., Liu, C.-Y., Wen, D., Gao, D.-Z., Lin, S., He, H., & Zhao, X.-F. (2022) · Translational research · doi:10.1016/j.trsl.2022.07.003 · Cited by 16
“Other molecular targets have also been shown to be biomarkers of cetuximab resistance, such as the MET proto-oncogene and fibroblast growth factor receptor 1 amplification, through candidate gene or comprehensive genomic analysis.(91) The application of transplant mouse models has advanced the understanding of adaptiv…”
BackgroundPharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer
Zafari, N., Velayati, M., Nassiri, M., Khazaei, M., Hassanian, S. M., Ferns, G. A., & Avan, A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220728152350 · Cited by 13
Bae, S.-W., Wang, J., Georgiou, D. K., Wen, X., Cohen, A. S., Geng, L., Tantawy, M. N., & Manning, H. C. (2023) · Tomography · doi:10.3390/tomography9020041 · Cited by 14
“However, only 12–17% of patients with wild-type (WT) kirsten rat sarcoma virus (KRAS) have durable responses to anti-EGFR monotherapy [6].”
BackgroundInvrea, F., Punzi, S., Petti, C., Minelli, R., Peoples, M. D., Bristow, C. A., Vurchio, V., Corrado, A., Bragoni, A., Marchiò, C., et al. (2021) · Cancers · doi:10.3390/cancers13153805 · Cited by 16
“Notably, even in the absence of known resistance mechanisms, EGFRtargeted therapy is not effective or durable in a non-negligible fraction of RAS/RAF wildtype (WT) cases [9,10].”
BackgroundSelf-citationYoshino, T., Uetake, H., Tsuchihara, K., Shitara, K., Yamazaki, K., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.001 · Cited by 15
“Genes will be selected to cover previously identified CRC-related pathways (RTK-RAS pathway, WNT pathway, transforming growth factor-beta pathway), CRC-related biological processes (DNA damage repair, CpG island methylation),(23,24) and pathways presumed relevant to acquired resistance of EGFR-targeted therapies (apop…”
BackgroundLindner, A. U., Carberry, S., Monsefi, N., Barat, A., Salvucci, M., O’Byrne, R., Zanella, E. R., Cremona, M., Hennessy, B. T., Bertotti, A., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33226 · Cited by 12
“identified to bear no somatic sequence alteration of the KRAS, NRAS, BRAF and PIK3CA genes as identified by exome sequencing with an average coverage within the target regions of nearly 150-fold for each sample.(9) Protein levels were quantitatively profiled by RPPA analysis of fresh-frozen pretreatment tumour samples…”
BackgroundMethodSelf-citationOncogenic kinase fusions: an evolving arena with innovative clinical opportunities
Tabbò, F., Pizzi, M., Kyriakides, P. W., Ruggeri, B., & Inghirami, G. (2016) · Oncotarget · doi:10.18632/oncotarget.7853 · Cited by 13
“Patientderived cancer models are indeed pivotal for drug discovery, for the characterization of cancer biology and for the assessment of personalized therapies [137-139].”
BackgroundGuo, S. J., Chen, D., Huang, X., Cai, J., Wery, J., & Li, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.10499 · Cited by 12
“First, a recent retrospective analysis of multiple phase-III trials unexpectedly concluded that patients with KRAS codon 13 mutation (G13D) seem to benefit from the treatment [6], and our recent observation on a mouse clinical trial (MCT) using a cohort of randomly selected CRC patient-derived xenografts (PDXs) also c…”
BackgroundResultInfluentialSelf-citationSchirripa, M., Zhang, W., Heinemann, V., Cao, S., Okazaki, S., Yang, D., Loupakis, F., Berger, M. D., Ning, Y., Miyamoto, Y., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30715 · Cited by 11
“cation and mutations of IRS2 were recently identified in tumors with increased sensitivity to anti-EGFR therapy.(12)”
BackgroundVaghi, C., Tosi, F., Mauri, G., Bonazzina, E., Amatu, A., Bencardino, K., Piscazzi, D., Roazzi, L., Villa, F., Maggi, M., et al. (2026) · Drugs · doi:10.1007/s40265-025-02253-2 · Cited by 11
“…the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway, similarly to RAS and BRAF V600E mutations, several preclinical studies have identified HER2 amplification in anti-EGFR resistant clones [15–17], thus leading to investigating it as potential biomarker for anti-EGFR treatment.”
Self-citationBerlin, J. D., Tolcher, A. W., Ding, C., Whisenant, J. G., Horak, I. D., Wood, D. L., Nadler, P. I., Hansen, U. H., Lantto, J., Skartved, N. J. Ø., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01217-7 · Cited by 12
Self-citationInhibition of Transketolase Improves the Prognosis of Colorectal Cancer
Zhang, L., Huang, Z., Cai, Q., Zhao, C., Xiao, Y., Quan, X., Tang, C., & Gao, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.837143 · Cited by 12
Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology
Rojas, G. (2022) · Antibodies · doi:10.3390/antib11030048 · Cited by 12
Chowdhury, S., Gupta, R., Millstein, J., Lin, K., Haridas, V., Zeineddine, M. A. A., Parseghian, C. M., Lenz, H., Kopetz, S., & Shen, J. P. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00422 · Cited by 12
Büttner, J., Jöhrens, K., Klauschen, F., Hummel, M., Lenze, D., Saeger, W., & Lehmann, A. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.01.007 · Cited by 14
The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy
Catalano, I., & Trusolino, L. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.001 · Cited by 12
Self-citationRossanese, O. W., Eccles, S. A., Springer, C. J., Swain, A., Raynaud, F. I., Workman, P., & Kirkin, V. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.07.002 · Cited by 13
Practice Implications of Expanded Genetic Testing in Oncology
Korngiebel, D. M., Zech, J. M., Chappelle, A. M., Burke, W., Carline, J. D., Gallagher, T. H., & Fullerton, S. M. (2019) · Cancer Investigation · doi:10.1080/07357907.2018.1564926 · Cited by 11
“Genomic profiling of somatic mutations in tumors is recommended by the National Comprehensive Cancer Network (NCCN) for some cancers to inform choice of molecularly targeted therapeutic agents such as cetuximab (1) or imatinib (2).”
BackgroundHeterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer
Grassi, E., Vurchio, V., Cresswell, G. D., Catalano, I., Lupo, B., Sassi, F. P., Galimi, F., Borgato, S., Ferri, M., Viviani, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado1641 · Cited by 12
Self-citationMa, J., Yang, Q., & Ling, Y. (2017) · BMC Cancer · doi:10.1186/s12885-017-3133-8 · Cited by 10
“A recent complete exome sequencing study identified mutations in ERBB2, EGFR, FGFR1, PDGFRA and MAP2K1 as potential drivers of resistance to EGFRtargeted therapies [18].”
BackgroundOhishi, T., Kato, Y., Kaneko, M. K., Ohba, S., Inoue, H., Harakawa, A., & Kawada, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176037 · Cited by 10
“EGFR signaling is initiated by the ligand binding of epidermal growth factor (EGF) family members to EGFR, leading to receptor dimerization and the subsequent activation of growth signals [2,4].”
BackgroundChen, K., Wang, H., Collins, G. P., Hollands, E. C., Law, I. Y. J., & Toh, J. W. T. (2022) · Current Oncology · doi:10.3390/curroncol29030116 · Cited by 11
“Abbreviations AJCC American Joint Committee on Cancer ALN Apical Lymph Node ASCO American Society of Clinical Oncology ASCRS American Society of Colon and Rectal Surgeons BRAF B-raf CDX2 Caudal Type Homeobox 2 CI confidence interval CRC colorectal cancer CRM circumferential resection margin CSS cancer specific surviva…”
BackgroundInfluential
Metadata
- Authors
- Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., Niknafs, N., Nesselbush, M., Lytle, K., Sassi, F., Cottino, F., Migliardi, G., Zanella, E. R., Ribero, D., Russolillo, N., Mellano, A., Muratore, A., Paraluppi, G., Salizzoni, M., Marsoni, S., Kragh, M., Lantto, J., Cassingena, A., Li, Q. K., Karchin, R., Scharpf, R., Sartore-Bianchi, A., Siena, S., Diaz, L. A., Trusolino, L., & Velculescu, V. E.
- Affiliations
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Johns Hopkins University (US)
- Candiolo Cancer Institute (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Symphogen (Denmark) (DK)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milan (IT)
- Corresponding author
- Bertotti, Andrea
- Trusolino, Livio
- Velculescu, Victor E.
- ORCID
- Bertotti, Andrea
- Papp, Eniko
- Jones, Siân
- Adleff, Vilmos
- Anagnostou, Valsamo
- Lupo, Barbara
- Sausen, Mark
- Phallen, Jillian
- Hruban, Carolyn A.
- Tokheim, Collin
- Niknafs, Noushin
- Nesselbush, Monica
- Sassi, Francesco
- Cottino, Francesca
- Migliardi, Giorgia
- Zanella, Eugenia R.
- Ribero, Dario
- Russolillo, Nadia
- Mellano, Alfredo
- Muratore, Andrea
- Salizzoni, Mauro
- Marsoni, Silvia
- Kragh, Michael
- Lantto, Johan
- Cassingena, Andrea
- Li, Qing Kay
- Karchin, Rachel
- Scharpf, Robert
- Siena, Salvatore
- Diaz, Luis A.
- Trusolino, Livio
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2015-09-30
- Volume
- 526
- Issue
- 7572
- Pages
- 263-267
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4878148
- OpenAlex
- W2102354469
- Cited by
- 479
- References
- 41
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 35 · 2022: 47 · 2021: 50 · 2020: 47 · 2019: 59 · 2018: 56 · 2017: 57 · 2016: 43 · 2015: 3
- FWCI
- 23.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-02-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- National Cancer Institute (R01-CA121113, CA-121113, P30CA006973)
- National Institute of General Medical Sciences (T32GM007057)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibition, anti-EGFR antibody therapy, cetuximab, panitumumab, treatment resistance, primary resistance, somatic mutations, ERBB2, FGFR1, PDGFRA, MEK1, KRAS wild-type
- MeSH terms
- Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Mutation, Colorectal Neoplasms, Genome, Human, Proto-Oncogene Proteins p21(ras), Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Receptor, Platelet-Derived Growth Factor alpha, Xenograft Model Antitumor Assays, Genomics, MAP Kinase Kinase 1, Mice, Receptor, Fibroblast Growth Factor, Type 1, Insulin Receptor Substrate Proteins, DNA Copy Number Variations, Molecular Targeted Therapy, Exome, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.